Half-life

2 h

Tmax

0.5 h

Category

peptide

Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone (GH) release from the pituitary. Unlike earlier GH secretagogues such as GHRP-6, ipamorelin shows minimal effect on cortisol and prolactin in early studies. Its short half-life of approximately 2 hours typically leads to protocols involving once- or twice-daily subcutaneous administration. Ipamorelin is frequently combined with a GHRH analogue (such as Mod GRF 1-29 or CJC-1295) to produce a synergistic GH pulse. Tracking dose timing relative to meals (GH secretion is suppressed by hyperglycaemia), injection site rotation, and any side effects is essential for evaluating response.

Mechanism

A selective growth-hormone secretagogue acting as a ghrelin receptor (GHS-R1a) agonist. Early studies describe growth-hormone release with comparatively little effect on cortisol or prolactin.

Research summary

Investigated as a growth-hormone secretagogue in early clinical and preclinical studies. It is not an FDA-approved therapeutic. Long-term human outcome data are limited.

Reported side effects

Reported effects in early studies include transient water retention, headache, and injection-site reactions. As a secretagogue, effects on growth hormone and IGF-1 warrant monitoring in a clinical context. The full profile is not established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Ipamorelin selectivity and GH-release studies · peer-reviewed endocrinology journals (1998)search PubMed for ipamorelin growth hormone
Growth hormone secretagogue reviews · peer-reviewed review articles (2015)context for the secretagogue class

References

Ipamorelin selectivity profileDOI: 10.1530/eje.0.1390552

TrackPep là ứng dụng theo dõi. Ứng dụng chỉ ghi lại những gì bạn nhập, không bao giờ đề xuất hay tính toán lượng dùng.